BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weir MR. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. Am J Nephrol 2021;52:450-66. [PMID: 34280923 DOI: 10.1159/000516901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhu Y, Tang Y, He H, Hu P, Sun W, Jin M, Wang L, Xu X. Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia. Front Cell Infect Microbiol 2022;12:919352. [DOI: 10.3389/fcimb.2022.919352] [Reference Citation Analysis]
2 Dhillon S. Desidustat: First Approval. Drugs 2022. [PMID: 35834123 DOI: 10.1007/s40265-022-01744-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Okamoto N, Inaguma D, Hayashi H, Koseki A, Iwamori T, Kudo M, Yuzawa Y. Prescription rate of erythropoietin-stimulating agents is low for patients with renal impairment under non-nephrology care in a tertiary-level academic medical center in Japan. Clin Exp Nephrol 2022. [PMID: 35230570 DOI: 10.1007/s10157-022-02194-0] [Reference Citation Analysis]
4 Crugliano G, Serra R, Ielapi N, Battaglia Y, Coppolino G, Bolignano D, Bracale UM, Pisani A, Faga T, Michael A, Provenzano M, Andreucci M. Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?". Int J Mol Sci 2021;22:12590. [PMID: 34830468 DOI: 10.3390/ijms222212590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]